(lp0
S'MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer PR Newswire  - Apr 3, 2017 SAN DIEGO, April 3, 2017 /PRNewswire/ -- MEI Pharma, Inc. , an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Brian Drazba as Chief Financial Officer.'
p1
aS'MEI Pharma, Inc.  Files An 8-K Departure of Directors or Certain ... Market Exclusive - Apr 3, 2017 On April 3, 2017, MEI Pharma, Inc.  announced the appointment of Brian G. Drazba as Chief Financial Officer and Secretary, effective immediately.'
p2
aS"MEI Pharma Inc  Poised To Move Higher; Here's Why Smarter Analyst - Apr 19, 2016 Having seen the updated Pracinostat overall survival data in elderly Acute Myeloid Leukemia  from MEI Pharma  presented at the recent Needham Healthcare Conference, I believe this is another opportunity to buy a severely&nbsp;..."
p3
aS'MEI Pharma to Present at Needham Healthcare Conference PR Newswire  - Mar 28, 2017 SAN DIEGO, March 28, 2017 /PRNewswire/ -- MEI Pharma, Inc. , an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.In focus: MEI Pharma, Inc.  Trading Patterns - Post Analyst'
p4
aS'MEI Pharma to Present at Oppenheimer Healthcare Conference Yahoo Finance - Feb 22, 2017 SAN DIEGO, March 14, 2017 /PRNewswire/ -- MEI Pharma, Inc. , an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.MEI Pharma, Inc.  Broker Price Targets For The Coming Week - Fiscal StandardIn Volatile Markets Do Analysts Think You Should Buy MEI Pharma, Inc. ? - The De Soto Edge'
p5
aS'MEI Pharma: Upcoming Catalysts Will Drive Stock Rebound Seeking Alpha  - Mar 24, 2015 The ~80% gain in MEI Pharma  in less than 2 months since my article was too much for me to pass up completely as I hedged my bet.MEI Pharma Announces Top-Line Data From Randomized Phase II Clinical Study Of ... - PR Newswire Can MEI Pharma Survive? - 24/7 Wall St.'
p6
aS'MEI Pharma Should Be Bought Ahead Of ASH Conference Seeking Alpha - Nov 4, 2015 Pracinostat Phase 2 data presented at ASH will illustrate survival benefit in AML and favorable outcomes in MDS patients. MEI Pharma also has two other promising clinical stage drugs in the pipeline with PWT143,  and a novel&nbsp;...'
p7
aS'MEI Pharma Undervalued As Pracinostat Advances To Phase 3 In AML Seeking Alpha - Dec 30, 2015 By all metrics, updated data presented at ASH detailing the efficacy of Pracinostat combo in elderly AML was impressive. Median OS of 14+ months and counting.'
p8
aS'Wedbush Top Analyst Remains Sidelined on MEI Pharma Inc  Despite ... Smarter Analyst - Aug 3, 2016 MEI Pharma Inc  just received Breakthrough Therapy Designation for its key pipeline drug pracinostat, anti-tumor molecule inhibitor that combined with azacitidine treats patients with newly diagnosed acute myeloid leukemia  who are&nbsp;...'
p9
aS'MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in ... PR Newswire  - Dec 7, 2015 SAN DIEGO, Dec. 7, 2015 /PRNewswire/ -- MEI Pharma, Inc. , an oncology company focused on the clinical development of novel therapies for cancer, today announced positive results from a Phase II study of its investigational drug candidate&nbsp;...'
p10
a.